Cell therapy company Cartherics has announced that chief operating officer Dr Ian Nisbet will present at the upcoming 2025 BIO International Convention in June.
Dr Nisbet will present - ‘Cartherics - Revolutionising Cellular Therapies for Cancer and Beyond’ - at the Boston event on 16 June. It will discuss the company’s pipeline, R&D activities, business objectives and investment goals.
The annual BIO International Convention is the world’s largest industry gathering. It provides an opportunity to engage with senior biotechnology executives, business development leaders and investors.
The company's proprietary platform leverages induced pluripotent stem cells (iPSC) to generate homogenous, natural killer (NK) cells using a scalable manufacturing process. The NK cells engineered to carry chimeric antigen receptors (CARs) for precision targeting of solid tumours and, potentially, endometriosis. It stated that its pipeline includes multiple assets with dual-targeting and immune evasion resistance, all of which are covered by strong patent protection.
CTH-401, Cartherics’ lead cell therapy candidate, is the only NK cell product in development that features a CAR targeting TAG-72, a well-established tumour marker broadly expressed across multiple adenocarcinomas, including ovarian, gastric, colorectal, prostate, and pancreatic cancers.
Cartherics has demonstrated that CTH-401 is highly effective in eliminating ovarian cancer cells in both tissue culture and animal models, with regulatory approval for the first clinical trial targeted for next year.
Dr Nisbet said, “Cartherics has established a powerful platform for generating an effectively unlimited supply of CAR-NK cells that are potential therapies for poorly treated and underserved diseases like cancer and endometriosis. BIO presents a fantastic opportunity to showcase this platform to the world.”
Cartherics said it thanks the Victorian government, Austrade and MTPConnect for financial and organisational support to attend BIO.
